INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Alnylam Pharmaceuticals, Inc. & Advises Investors with Losses t...
October 06 2016 - 5:23PM
Business Wire
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it
is investigating Alnylam Pharmaceuticals, Inc. (“Alnylam” or the
“Company”) (Nasdaq: ALNY) concerning possible violations of federal
securities laws.
If you purchased or otherwise acquired Alnylam shares and would
like more information regarding the investigation, we advise you to
contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999
Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at
800-977-7401, to discuss your rights without cost to you. You can
also reach us through the firm’s website at
http://www.Goldberglawpc.com, or by email at
info@goldberglawpc.com.
The investigation concerns whether the Company violated Sections
10(b) and 20(a) of the Securities Exchange Act of 1934. On October
5, 2016 Alnylam announced that it would discontinue development of
revusiran (an investigational RNA interference therapeutic for the
treatment of hereditary ATTR amyloidosis with cardiomyopathy) due
to patient safety concerns. The Company stated that reports
indicated patients taking revusiran in midstage trials had new or
worsening complications of the disease. When this information
became public, shares of Alnylam dropped in value.
If you have any questions concerning your legal rights, please
immediately contact Goldberg Law PC at 800-977-7401, or visit our
website at http://www.Goldberglawpc.com, or email us at
info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and
specializes in securities class actions and shareholder rights
litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161006006489/en/
Goldberg Law PC, Los AngelesMichael Goldberg, Esq.,
800-977-7401Brian Schall, Esq.,
800-977-7401info@goldberglawpc.comhttp://www.Goldberglawpc.com
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024